Analgesia Clinical Trial
Official title:
Effect of Bilateral Quadratus Lumborum Block for Pain Relief in Patients With Cesarean Section
Cesarean section commonly induces moderate to severe pain for 48 hours. These patients have
additional compelling reasons to provide adequate pain relief as early mobilization is a key
factor to prevent the risk of thromboembolic event which is increased during pregnancy.
Beside these, patients need to be pain free to takecare for their newborn and breastfeed
them. Poorly controlled pain after cesarean section also increases risk of chronic pain and
postpartum depression.
Intrathecal morphine is considered the "gold standard" for postoperative pain relief after
cesarean delivery. The duration of analgesic effect of morphine extend to 12-24 hours. Its
widespread use is due to its favorable pharmacokinetic profile, ease of administration and
low cost. Although intrathecal morphine is highly effective, its use is associated with
undesirable adverse effect particularly nausea, vomiting and pruritus which reduce overall
patients' satisfaction. More serious complication is the risk of delayed maternal respiratory
depression.
The Quadratus Lumborum block was first described in 2007 which demonstrates a spread to the
paravertebral space, thus leads to a more extensive block to T5-L1 nerve branches and a long
lasting block with the potential to provide visceral pain relief. Therefore, this block has
an evolving role in postoperative analgesia for many lower abdominal surgeries. As the safety
is concerned, there has been one report of a patient with unilateral hip flexion and knee
extension weakness leading to unplanned overnight admission following lateral quadratus
lumborum block after laparoscopic gynaecological operation.
If the result favors effective, it will have the advantage of a combination with intrathecal
opioid to prolong the pain free period after cesarean section which has about 4,000 cases per
year.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05534230 -
Dexmedetomidine for Pain Reduction in CABG
|
N/A | |
Recruiting |
NCT06275698 -
HONEY for the Treatment of POst-Tonsillectomy Pain
|
N/A | |
Recruiting |
NCT04436224 -
Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation
|
Phase 4 | |
Not yet recruiting |
NCT04548323 -
Hypoalgesic Effects of Walking and Running Imagined
|
||
Completed |
NCT06054945 -
Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
|
||
Completed |
NCT04394481 -
Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery
|
Phase 4 | |
Completed |
NCT04690647 -
The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement.
|
N/A | |
Completed |
NCT05034601 -
ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure
|
N/A | |
Completed |
NCT03740815 -
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
|
N/A | |
Recruiting |
NCT05454202 -
Assessment of the Interest of ANI in the Non-communicating Patient in Palliative Care
|
||
Recruiting |
NCT04554186 -
Serratus Anterior Plane Block Versus Thoracic Paravertebral Block.
|
N/A | |
Suspended |
NCT04860635 -
Safety of F14 Following Total Knee Replacement
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06393777 -
Effectiveness of Pre-administered Natural Sweet-tasting Solution (Honey) for Decreasing Pain of Needle Insertion
|
N/A | |
Not yet recruiting |
NCT04519463 -
The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing
|
Early Phase 1 | |
Completed |
NCT02916342 -
Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks
|
Phase 4 | |
Completed |
NCT03206554 -
Local Infiltration Analgesia in Total Knee Arthroplasty
|
Phase 2 | |
Not yet recruiting |
NCT02549118 -
Tenoxicam for Intrapartum Analgesia
|
Phase 2 | |
Not yet recruiting |
NCT02190760 -
Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block.
|
N/A | |
Completed |
NCT01789606 -
Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet
|
Phase 3 | |
Completed |
NCT01299584 -
ULTIVA Post Marketing Surveillance
|
N/A |